otezla
Celgene’s Otezla becomes first and only FDA-approved therapy for oral ulcers in Behçet’s Disease
July 22, 2019Sales and Marketing Behçet's disease, Behçet’s Disease, Celgene, apremilast, otezla, pharma
Celgene has revealed the US approval of Otezla (apremilast), confirming that the FDA awarded marketing authorisation for the treatment of …
Bristol-Myers Squibb to sell off Celgene’s Otezla ahead of $74 billion merger
June 24, 2019Manufacturing and Production Bristol-Myers Squibb, Celgene, FTC, otezla, pharma, psoriasis
Bristol-Myers Squibb has agreed to sell off Celgene’s psoriasis treatment Otezla, to appease antitrust regulators. BMS will divest one of …
Celgene’s Otezla produces “meaningful benefits” beyond traditional metrics in plaque psoriasis
September 13, 2018Research and Development Celgene, otezla, pharma, psoriasis
Celgene made its voice heard amongst the chorus of new psoriasis data emerging from the European Academy of Dermatology and …
Celgene showcases strong Otezla data in psoriatic arthritis
June 13, 2018Research and Development Celgene, EULAR, otezla, pharma
Celgene has seized the opportunity at the Annual European Congress of Rheumatology in Amsterdam to reveal positive new data for …
Celgene reveals strong P3 Otezla data in rare inflammatory condition
February 19, 2018Research and Development, Sales and Marketing Behçet's disease, Celgene, apremilast, otezla, pharma
Celgene has lifted the curtain on strong new Phase 3 data for its phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in …
Top Ten most popular articles on Pharmafile.com this week
November 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten
While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …
Celgene’s Otezla hits primary endpoint in psoriatic arthritis study
November 15, 2016Manufacturing and Production, Research and Development Celgene, otezla, psoriatic arthritis
Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment …
Celgene’s Otezla approved by NICE for chronic plaque psoriasis
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, NICE, apremilast, otezla
NICE has given its approval to another indication for Celgene’s Otezla (apremilast), meaning NHS patients now have access to the …
NICE backs Celgene’s Otezla for psoriatic arthritis
October 12, 2016Research and Development, Sales and Marketing Celgene, NICE, otezla
The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …
New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs
December 16, 2015Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin
NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …
NICE rejects Otelza but SMC recommends it
June 11, 2015Sales and Marketing Astellas, Celgene, NHS, NICE, SMC, Xtandi, otezla
Draft guidance issued by NICE has seen rejections for products including Celgene’s Otelza and Astellas Pharma’s Xtandi, and a call …
Pfizer, Novartis and Celgene among late-stage psoriasis trial advances
March 23, 2015Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib
Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …
Latest content
Five Facts about cardiovascular disease
